Public release of Virbac Annual Report at 31 December 2023 (ESEF format). The Group released and filed its 2023 Annual Report with the French Autorit© des march©s financiers. The...
KEY FIGURESRevenue1st quarter 2024 ‚345.7MGrowth at constant exchange rates and scope1 +9.7% of which companion animals +16.2%farm animals +1.2%Growth at constant exchange...
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the...
On April 1, we successfully completed the acquisition of Sasaeah. This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle...
Revenue up 4.9%, enabling market share gains despite difficulties in 20232023 operating profitability1 at an all-time high of 23.2% of revenue Up 0.4 points compared to 2022 Strong momentum...
Public release of Virbac Consolidated Accounts at 31 December 2023. The Group released its 2023 Consolidated Accounts. The document is available on the corporate website, at corporate.virbac.com,...
Virbac : Declaration of the number of shares and voting rights 02/2024
Virbac to take a leading position in Japan through the acquisition of Sasaeah
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the...
KEY FIGURESAnnualRevenue 2023 ‚¬1,246.9 millionGrowth at constant exchange rates and scope1 +4.9% of whichcompanion animals +3.5% farm animals +6.7%Growth at constant exchange rates +4.9% Overall...